View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

Title:
United Kingdom-Salisbury: PBL ICT Infrastructure
Document Ref:
589007-2019
Document Type:
Prior information notice with call for competition
Published By:
Porton Biopharma
Date Published:
12 December 2019
Deadline Date:
24 January 2020
Document Source:
Framework/DPS:
No
Alert Profile:
Labels:

Notice Abstract

Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a 5-year technical strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the pilot is expected to be circa 6 months.

Notice Details

Prior information notice

This notice is a call for competition

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting Change entity

I.1) Name and addresses

Porton Biopharma

Salisbury

UK

E-mail: jeff.pike@portonbiopharma.com

NUTS: UKK1

Internet address(es)

Main address: https://www.portonbiopharma.com/

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://portonbiopharma.bravosolution.co.uk


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://portonbiopharma.bravosolution.co.uk


Tenders or requests to participate must be sent to the abovementioned address


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

PBL ICT Infrastructure

II.1.2) Main CPV code

72000000

 

II.1.3) Type of contract

Services

II.1.4) Short description

Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a 5-year technical strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the pilot is expected to be circa 6 months.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS code:

UKK1

II.2.4) Description of the procurement

Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a 5-year technical strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the Pilot is expected to be circa 6 months.

Having been fully dependent on Public Health England (PHE) ICT services and infrastructure since its inception in 2015, it is strategically important for PBL to now establish a completely new and independent ICT operation.

The following technical strategy has been approved for implementation. Within the limited scope of a Pilot phase, ICT services organisations are invited to express an interest in designing, supplying and building this environment in close collaboration with a dedicated PBL team, on a fixed-price basis.

— HCI-based hosting platform – currently specified as Dell-EMC VxRail stretch-cluster,

— physical network underlay (limited scope),

— perimeter firewall (to be specified),

— SDN network overlay technology (circa 30 endpoints) – currently specified as Cisco’s SDA solution,

— Horizon VDI for application and desktop virtualisation (2-3 pilot application environments).

— MS Windows domain(s) dedicated to PBL – including all domain-related services and inter-domain trust for testing purposes,

— coherent IDAM/RBAC ecosystem.

The Pilot infrastructure will form the basis of a broader enterprise ICT core infrastructure that will be built-out in subsequent programme phases.

PBL operates within a highly regulated pharmaceutical environment (within FDA and MHRA codes/guidance for GMP IT). Close collaboration with PBL and adherence to ITIL principles and local IT infrastructure qualification controls will be critical to ensure compliance with regulatory standards from day-1.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

III.2) Conditions related to the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Restricted procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of expressions of interest

Date: 24/01/2020

Local time: 17:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

Section VI: Complementary information

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

VI.4) Procedures for review

VI.4.1) Review body

Porton Biopharma

Salisbury

UK

VI.5) Date of dispatch of this notice

10/12/2019

Current Notes